<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00638911</url>
  </required_header>
  <id_info>
    <org_study_id>502.465</org_study_id>
    <nct_id>NCT00638911</nct_id>
  </id_info>
  <brief_title>Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension</brief_title>
  <official_title>PMS Assessing the Safety and Efficacy of Telmisartan in Patients With Mild-to-moderate Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of this therapeutic observation is to demonstrate the efficacy and safety of
      telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate
      essential hypertension under normal conditions of use after market launch.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study 502.465(NCT00638911) was planned and conducted as 6 independent substudies with varying
      country participation. One study database, a data management plan or a TSAP were not planned
      and do not exist which precludes baseline and outcome analyses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoints will be the change from baseline in mean systolic blood pressure.</measure>
    <time_frame>4-24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoints are clinical control of the BP and response rate.</measure>
    <time_frame>4-24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary Endpoints will be discontinuations and tolerability.</measure>
    <time_frame>4-24 Weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">33247</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Patients with hypertention</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Male or female patients over the age of 18 years, with mild-to-moderate essential
        hypertension with values of mean morning seated diastolic BP more than 90 mmHg and less
        than 109 mmHg and or mean morning seated systolic BP more than 140 mmHg and less than 180
        mmHg

          1. newly diagnosed patients

          2. patients failing to reach target blood pressure of less than 140 on 90 on their
             current antihypertensive treatment

        Exclusion criteria:

          1. Pre-menopausal women who do not use adequate contraception who are pregnant or nursing

          2. Cholestasis and biliary obstructive disorders

          3. Severe hepatic impairment

          4. Severe renal impairment creatinine clearance less than 30 ml pro min

          5. Refractory hypokalaemia hypercalcaemia

          6. Known hypersensitivity to any component in the formulation of Micardis/Micardis Plus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
  </removed_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2008</study_first_submitted>
  <study_first_submitted_qc>March 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2008</study_first_posted>
  <last_update_submitted>May 18, 2012</last_update_submitted>
  <last_update_submitted_qc>May 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

